On 05/10/19 [10:39], Rumor Hound alerted potential takeover of Portola Pharmaceuticals, (Nasdaq: $PTLA, $30.93) where no potential acquirer was mentioned. PTLA markets therapies Bevyxxa (betrixaban; Factor Xa inhibitor), an oral anticoagulant and Andexxa (andexanet alfa; coagulation factor Xa (recombinant), inactivated-zhzo) and is developing Cerdulatinib, an oral tx for follicular lymphoma (FL) in PhIIa and PRT2761 for allergic conjunctivitis.
PTLA announced Andexxa was added to the National Comprehensive Cancer Network (NCCN) guidelines- and in their most recent earnings presentation, demand was “strong” and “growing”. The oral formulation is advantageous for patients versus traditional injection administration. PTLA’s reach into 300 hospitals coupled to three consecutive quarters of strong revenue growth and U.S. + EU approval brings PTLA’s novel tx to an ever increasing market opportunity of up to 200-300K patients by 2025.
In light of the above commentary, this rumor may be substantiated by the opinion that PTLA would offer two robust pipeline catalysts and two strong revenue-driving products- allowing a potential acquirer to accrue significant revenues and integrate a new segment to their product portfolio.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.